FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:681-682 September 8, 1994 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Haddow, J. E. Related Article by Kinch, J. W.

To the Editor: Haddow et al. (April 21 issue)¹ report that among pregnant women 35 years of age or older, screening serum for three substances (alpha-fetoprotein, human chorionic gonadotropin, and estriol) can identify 89 percent of fetuses with Down's syndrome, with a false positive rate of 25 percent. We must distinguish how these results relate to individual women (i.e., the effect on patient care) from their effect in larger populations (i.e., the implications for public policy). The authors seem to suggest that preference should be given to the latter.

The practicing physician is concerned with individual pregnant women. The challenge . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.